索马托斯坦因子受体导向的治疗药物在静脉神经母细胞瘤中
Yingjun Zhi1, Sebastian E Serfling2, Daniel Groener3,4,5
1Departments of Otorhinolaryngology, Head and Neck Surgery.
Clinical nuclear medicine
|March 3, 2025
概括
针对体静止素受体 (SSTR) 的PET/CT成像显示在先进的静脉神经母细胞瘤 (ENB) 中具有很高的对比度. 针对SSTR的受体放射性核酸治疗 (PRRT) 是对ENB的可行和安全的治疗选择.
科学领域:
- 在瘤学瘤学.
- 核医学是一种核医学.
- 辐射疗法 辐射疗法
背景情况:
- 静脉神经母细胞瘤 (ENB) 是一种罕见的恶性瘤.
- 先进的ENB带来了治疗挑战.
- 在ENB中观察到体静止素受体 (SSTR) 表达.
研究的目的:
- 在ENB中评估SSTR向分子成像.
- 评估SSTR向性受体放射性核酸治疗 (PRRT) 在ENB中的疗效和安全性.
- 为了确定治疗反应和无进展生存期 (PFS).
主要方法:
- 五名患有晚期ENB的患者接受了SSTR导向的PET/CT.
- 量化了瘤体积 (TV),最大SUV (SUVmax) 和目标与背景比率 (TBR).
- 用剂量计进行PRRT,并使用CTCAE v5.0.0监测毒性 (毒性,血液毒性).
主要成果:
- SSTR-PET/CT显示出高图像对比度,TBR中位数为19.8±9.7.
- 确定了32个SSTR-avid病变,中位数TV为11.7±10.8和SUV最大值为24.3±12.8.
- 在没有3/4级血毒性或毒性的情况下,PRRT是可行的; 一名患者患有可逆的3级贫血. 在60%的患者中观察到部分反应,PFS的中位数为29周.
结论:
- 通过SSTR导向的PET/CT提供了ENB的优秀可视化.
- 针对SSTR的PRRT是一种安全且潜在的有效治疗先进ENB的方法.
- 以SSTR为目标的超声波代表了管理先进ENB的有前途的方法.
更多相关视频
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
17.4K
07:31A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
3.5K
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
